Cisplatin‐based IC followed by CCRT is the recommended treatment for patients with LANPC, which can reduce the risk of disease progression of LANPC.[5, 6, 32] However, ≈20% of patients with NPC develop disease progression due to treatment failure.[1, 6, 10] Drug resistance is a major factor preventing complete remission and contributing to poor survival outcomes for patients with LANPC, creating a significant burden on patients and their families.[6, 8] In this study, we identified that DDAH1, a novel molecular marker, promoted NPC cisplatin resistance. This evidence concerns the gene DDAH1 and nasopharyngeal carcinoma.